SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Callegari Simone PhD 1981 )
 

Search: WFRF:(Callegari Simone PhD 1981 ) > Challenges and shor...

Challenges and shortcomings of antibacterial discovery projects

Theuretzbacher, Ursula (author)
Ctr Anti Infect Agents, Vienna, Austria.;Ctr Antiinfect Agents, A-1180 Vienna, Austria.
Baraldi, Enrico, Professor, 1970- (author)
Uppsala universitet,Industriell teknik
Ciabuschi, Francesco, 1973- (author)
Uppsala universitet,Företagsekonomiska institutionen
show more...
Callegari, Simone, PhD, 1981- (author)
Uppsala universitet,Institutionen för informatik och media
show less...
Ctr Anti Infect Agents, Vienna, Austria;Ctr Antiinfect Agents, A-1180 Vienna, Austria. Industriell teknik (creator_code:org_t)
Elsevier, 2023
2023
English.
In: Clinical Microbiology and Infection. - : Elsevier. - 1198-743X .- 1469-0691. ; 29:5, s. 610-615
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • ObjectivesAntibacterial drug discovery activities are essential for filling clinical pipelines with promising clinical candidates. Little information is available about the challenges and shortcomings of small companies and academic institutions in performing these important discovery tasks.MethodsWe performed a content analysis of 463 reviewer comments on 91 funding applications of antibacterial drug discovery projects submitted to two major global funders between 2016 and 2020 that had not proceeded further in the selection process. This quality assessment was complemented with the inputs (via e-mail) from a panel involving six antibiotic research and development (R&D) experts with long-standing expertise and experience in antibiotic drug discovery.ResultsCommon critical comments of reviewers are grouped into three main categories: scientific and technical shortcomings, unclear potential societal impact, and insufficient capability and expertise of the project team regarding the R&D process. Insufficient characterization of in vitro activity and/or testing of the hits/leads and insufficient antibacterial activity were the most common critical comments. Other areas of concern were insufficient or lack of differentiation from available drugs or projects with a long R&D history, and the research team's insufficient knowledge of a structured streamlined R&D process as reflected in severe gaps in the expertise of the R&D team. Little appreciation for the problem of the emergence of target-based resistance, especially in single-target approaches, and little awareness of toxicological issues, including approaches with historical liabilities were also commonly mentioned. The shortcomings identified through the analysis of funding applications are echoed by the results of the expert panel.DiscussionOur analysis identified an urgent need of strengthening the support for antibacterial drug discovery teams to help more projects reach such a quality to be eligible for global funders and private investors.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)
NATURVETENSKAP  -- Data- och informationsvetenskap -- Annan data- och informationsvetenskap (hsv//swe)
NATURAL SCIENCES  -- Computer and Information Sciences -- Other Computer and Information Science (hsv//eng)

Keyword

Antibiotics
Antibacterial pipelines
Drug discovery
Expert panel
Funding applications

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view